Compare BCG & CING Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BCG | CING |
|---|---|---|
| Founded | 2016 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 29.6M | 26.4M |
| IPO Year | N/A | 2021 |
| Metric | BCG | CING |
|---|---|---|
| Price | $1.99 | $4.21 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $31.33 |
| AVG Volume (30 Days) | ★ 2.0M | 122.1K |
| Earning Date | 11-13-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.04 | N/A |
| Revenue | ★ $178,203,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $57.50 | ★ N/A |
| Revenue Growth | ★ 10.19 | N/A |
| 52 Week Low | $1.36 | $3.20 |
| 52 Week High | $6.00 | $6.01 |
| Indicator | BCG | CING |
|---|---|---|
| Relative Strength Index (RSI) | 46.39 | 61.63 |
| Support Level | $2.33 | $3.75 |
| Resistance Level | $3.07 | $4.02 |
| Average True Range (ATR) | 0.33 | 0.23 |
| MACD | -0.06 | 0.07 |
| Stochastic Oscillator | 8.32 | 76.01 |
Binah Capital Group Inc formerly Wentworth Management Services LLC is a holding company that acquires and manages businesses in the wealth management industry. The company specializes in consolidating independent broker-dealers to capture economies of scale needed to service financial advisors in today's technology-enabled regulatory environment. Wentworth's core philosophy focuses on building long-term, productive relationships with its advisor base.
Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic area to use PTR technology to develop future product candidates.